xGen® Pan-Cancer Panel
Enrich for genes implicated in several
cancers
The xGen Pan-Cancer Panel v1.5 consists of
7816 xGen Lockdown® Probes, spanning 800 kb of the human
genome, for enrichment of 127 significantly mutated genes implicated across
12 tumor tissue types for deeper sequencing coverage.
- Obtain high coverage uniformity across all targets
- Detect variations reliably with high reproducibility and
increased depth of coverage
- Enjoy fast turnaround via easy online ordering and next day
shipping
xGen Pan-Cancer Panel
|
Product |
|
|
16 rxn xGen® Pan-Cancer Panel v1.5 |
|
|
96 rxn xGen® Pan-Cancer Panel v1.5 |
|
Every year, ~500 people in every 100,000
are diagnosed with cancer. Of these, 34% will not survive past five years.
Cancer resulted in more than 500,000 deaths in 2013 alone [1]. Next generation
sequencing has enabled the discovery and characterization of gene-specific
mutations that have the potential to be tumorigenic; however, the technology
also implicates a large number of genes that are not relevant to an
individual’s cancerous state. A shortlist of mutated genes that are relevant to
a multitude of cancer types, and that can be expanded to include additional
cancer type–specific genes, would be invaluable in clinical and research
applications. The Cancer Genome Atlas (TCGA) network performed a systematic
analysis of more than 3000 tumors from 12 cancer types to investigate
underlying mechanisms of cancer initiation and progression and have identified
127 significantly mutated genes (SMGs) across these tumor types [2].
The xGen Pan-Cancer Panel is a hybrid
capture panel based on the findings of the TCGA network. The panel comprises
xGen Lockdown Probes, individually synthesized and quality controlled 120mer
oligonucleotides bearing a 5′ biotin modification and manufactured using
proprietary Ultramer® synthesis technology.
References
- SEER Stat Fact Sheets: All Cancer Sites. National Cancer
Institute. Surveillance, Epidemiology, and End Results Program. http://seer.cancer.gov/statfacts/html/all.html.
(Accessed Feb 2014.)
- Kandoth C, McLellan MD, et al. (2013) Mutational landscape
and significance across 12 major cancer types. Nature, 502:333–339.
IDT